Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
280 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thrombosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Thrombosis - Pipeline Review, H2 2015', provides an overview of the Thrombosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thrombosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Thrombosis Overview 11 Therapeutics Development 12 Pipeline Products for Thrombosis - Overview 12 Pipeline Products for Thrombosis - Comparative Analysis 13 Thrombosis - Therapeutics under Development by Companies 14 Thrombosis - Therapeutics under Investigation by Universities/Institutes 19 Thrombosis - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Thrombosis - Products under Development by Companies 24 Thrombosis - Products under Investigation by Universities/Institutes 30 Thrombosis - Companies Involved in Therapeutics Development 32 3SBio Inc. 32 Antibe Therapeutics, Inc. 33 Archemix Corp. 34 Arena Pharmaceuticals, Inc. 35 Armetheon, Inc. 36 Arrowhead Research Corporation 37 Astellas Pharma Inc. 38 AstraZeneca Plc 39 Bayer AG 40 Bristol-Myers Squibb Company 41 Cardax Pharmaceuticals, Inc. 42 Cereno Scientific AB 43 China Biologic Products, Inc. 44 CSL Limited 45 Daewoong Pharmaceutical Co., Ltd. 46 Daiichi Sankyo Company, Limited 47 Dyax Corp. 48 Eisai Co., Ltd. 49 F. Hoffmann-La Roche Ltd. 50 Gamma Therapeutics, Inc. 51 Generex Biotechnology Corporation 52 GlycoMimetics, Inc. 53 Green Cross Corporation 54 IMMD Inc. 55 Isis Pharmaceuticals, Inc. 56 Johnson & Johnson 57 Laboratorios Farmaceuticos Rovi, S.A. 58 LG Life Science LTD. 59 Lipicard Technologies Limited 60 Merrion Pharmaceuticals Plc 61 Nihon Pharmaceutical Industry Co., Ltd. 62 Nostrum Pharmaceuticals, LLC 63 Pfizer Inc. 64 PLx Pharma Inc. 65 Portola Pharmaceuticals, Inc. 66 Prothix BV 67 Sagene Pharmaceuticals, Inc. 68 Sanofi 69 SciFluor Life Sciences, LLC 70 The International Biotechnology Center (IBC) Generium 71 Zedira GmbH 72 Zydus Cadila Healthcare Limited 73 Thrombosis - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Combination Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 AB-012 - Drug Profile 87 alteplase biosimilar - Drug Profile 89 Antisense RNAi Oligonucleotide for DVT - Drug Profile 90 antithrombin III (human) - Drug Profile 91 ANV-6L15 - Drug Profile 92 apixaban - Drug Profile 93 ARC-15105 - Drug Profile 95 ARCF-12 - Drug Profile 96 AS-1468240 - Drug Profile 97 ASP-1645 - Drug Profile 98 ASP-6537 - Drug Profile 99 aspirin - Drug Profile 100 ATB-340 - Drug Profile 102 BAY-1213790 - Drug Profile 103 betrixaban - Drug Profile 104 Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile 106 BMS-262084 - Drug Profile 107 BMS-593214 - Drug Profile 108 BMS-654457 - Drug Profile 109 BMS-816106 - Drug Profile 110 BMS-884775 - Drug Profile 111 BMS-986120 - Drug Profile 112 BMS-986141 - Drug Profile 113 BMS-986177 - Drug Profile 114 C-3 - Drug Profile 115 CDX-085 - Drug Profile 116 CSL-312 - Drug Profile 118 DD-2 - Drug Profile 119 Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis - Drug Profile 120 Drugs for Thrombosis - Drug Profile 121 DS-9231 - Drug Profile 122 DWJ-1261 - Drug Profile 123 DWJ-1355 - Drug Profile 124 DX-4012 - Drug Profile 125 E-5539 - Drug Profile 126 edoxaban tosylate - Drug Profile 127 enoxaparin biosimilar - Drug Profile 129 ER-410660 - Drug Profile 130 fondaparinux sodium - Drug Profile 131 fondaparinux sodium - Drug Profile 132 Gammarin - Drug Profile 133 GCC-2107 - Drug Profile 134 GMI-1271 - Drug Profile 135 IMD-4852 - Drug Profile 136 ISIS-FVIIRx - Drug Profile 137 ISIS-FXIRx - Drug Profile 138 JNJ-375 - Drug Profile 139 LC-231306 - Drug Profile 140 LT-5121 - Drug Profile 141 LT-5122 - Drug Profile 142 LT-5521 - Drug Profile 143 Lysimab - Drug Profile 144 Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile 145 nadroparin calcium - Drug Profile 146 NPB-06 - Drug Profile 147 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 148 Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile 150 PF-00190434 - Drug Profile 151 Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile 152 PRO-01 - Drug Profile 153 Protein for Thromboembolism - Drug Profile 154 PRT-060318 - Drug Profile 156 PZ-128 - Drug Profile 157 Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 159 Recombinant Protein for Thrombosis and Stroke - Drug Profile 160 Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 161 Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 162 rGPG-290 - Drug Profile 163 rivaroxaban - Drug Profile 164 S-002333 - Drug Profile 170 S-007867 - Drug Profile 171 SAR-216471 - Drug Profile 172 selegiline + Antiplatelet Drugs - Drug Profile 173 semuloparin sodium - Drug Profile 174 Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile 175 Small Molecule for Thrombosis - Drug Profile 176 Small Molecule for Thrombosis - Drug Profile 177 Small Molecule to Antagonize P2Y12 for Thrombosis - Drug Profile 178 Small Molecule to Antagonize PAR4 for Thromboembolic Disorders - Drug Profile 179 Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile 180 Small Molecule To Inhibit Factor Xa for Thrombosis - Drug Profile 181 Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile 182 Small Molecules for Hematological Disorders and Cancer - Drug Profile 183 Small Molecules for Thrombosis - Drug Profile 184 Small Molecules to Inhibit Carboxypeptidase U for Thrombosis - Drug Profile 185 Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile 186 Small Molecules to Inhibit Factor XIII for Thrombosis - Drug Profile 187 Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile 188 Small Molecules to Inhibit P2Y12 Receptor for Thrombosis - Drug Profile 189 Small Molecules to Inhibit PDI for Thrombosis - Drug Profile 190 SMRX-11 - Drug Profile 191 Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile 192 Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis - Drug Profile 193 TAP-ANV - Drug Profile 194 tecarfarin sodium - Drug Profile 195 temanogrel hydrochloride - Drug Profile 197 ticagrelor - Drug Profile 198 TM-5275 - Drug Profile 202 TM-5509 - Drug Profile 203 TRX-1 - Drug Profile 204 TTS-01 - Drug Profile 205 UM-8190 - Drug Profile 206 YG-001 - Drug Profile 207 Thrombosis - Recent Pipeline Updates 208 Thrombosis - Dormant Projects 246 Thrombosis - Discontinued Products 256 Thrombosis - Product Development Milestones 260 Featured News & Press Releases 260 Appendix 272 Methodology 272 Coverage 272 Secondary Research 272 Primary Research 272 Expert Panel Validation 272 Contact Us 272 Disclaimer 273
List of Tables
Number of Products under Development for Thrombosis, H2 2015 19 Number of Products under Development for Thrombosis - Comparative Analysis, H2 2015 20 Number of Products under Development by Companies, H2 2015 22 Number of Products under Development by Companies, H2 2015 (Contd..1) 23 Number of Products under Development by Companies, H2 2015 (Contd..2) 24 Number of Products under Development by Companies, H2 2015 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2015 27 Comparative Analysis by Late Stage Development, H2 2015 28 Comparative Analysis by Clinical Stage Development, H2 2015 29 Comparative Analysis by Early Stage Development, H2 2015 30 Products under Development by Companies, H2 2015 31 Products under Development by Companies, H2 2015 (Contd..1) 32 Products under Development by Companies, H2 2015 (Contd..2) 33 Products under Development by Companies, H2 2015 (Contd..3) 34 Products under Development by Companies, H2 2015 (Contd..4) 35 Products under Development by Companies, H2 2015 (Contd..5) 36 Products under Investigation by Universities/Institutes, H2 2015 37 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 38 Thrombosis - Pipeline by 3SBio Inc., H2 2015 39 Thrombosis - Pipeline by Antibe Therapeutics, Inc., H2 2015 40 Thrombosis - Pipeline by Archemix Corp., H2 2015 41 Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015 42 Thrombosis - Pipeline by Armetheon, Inc., H2 2015 43 Thrombosis - Pipeline by Arrowhead Research Corporation, H2 2015 44 Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015 45 Thrombosis - Pipeline by AstraZeneca Plc, H2 2015 46 Thrombosis - Pipeline by Bayer AG, H2 2015 47 Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015 48 Thrombosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 49 Thrombosis - Pipeline by Cereno Scientific AB, H2 2015 50 Thrombosis - Pipeline by China Biologic Products, Inc., H2 2015 51 Thrombosis - Pipeline by CSL Limited, H2 2015 52 Thrombosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 53 Thrombosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 54 Thrombosis - Pipeline by Dyax Corp., H2 2015 55 Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015 56 Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 57 Thrombosis - Pipeline by Gamma Therapeutics, Inc., H2 2015 58 Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2015 59 Thrombosis - Pipeline by GlycoMimetics, Inc., H2 2015 60 Thrombosis - Pipeline by Green Cross Corporation, H2 2015 61 Thrombosis - Pipeline by IMMD Inc., H2 2015 62 Thrombosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 63 Thrombosis - Pipeline by Johnson & Johnson, H2 2015 64 Thrombosis - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015 65 Thrombosis - Pipeline by LG Life Science LTD., H2 2015 66 Thrombosis - Pipeline by Lipicard Technologies Limited, H2 2015 67 Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015 68 Thrombosis - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2015 69 Thrombosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015 70 Thrombosis - Pipeline by Pfizer Inc., H2 2015 71 Thrombosis - Pipeline by PLx Pharma Inc., H2 2015 72 Thrombosis - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 73 Thrombosis - Pipeline by Prothix BV, H2 2015 74 Thrombosis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015 75 Thrombosis - Pipeline by Sanofi, H2 2015 76 Thrombosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015 77 Thrombosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 78 Thrombosis - Pipeline by Zedira GmbH, H2 2015 79 Thrombosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 80 Assessment by Monotherapy Products, H2 2015 81 Assessment by Combination Products, H2 2015 82 Number of Products by Stage and Target, H2 2015 84 Number of Products by Stage and Mechanism of Action, H2 2015 88 Number of Products by Stage and Route of Administration, H2 2015 91 Number of Products by Stage and Molecule Type, H2 2015 93 Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015 215 Thrombosis - Dormant Projects, H2 2015 253 Thrombosis - Dormant Projects (Contd..1), H2 2015 254 Thrombosis - Dormant Projects (Contd..2), H2 2015 255 Thrombosis - Dormant Projects (Contd..3), H2 2015 256 Thrombosis - Dormant Projects (Contd..4), H2 2015 257 Thrombosis - Dormant Projects (Contd..5), H2 2015 258 Thrombosis - Dormant Projects (Contd..6), H2 2015 259 Thrombosis - Dormant Projects (Contd..7), H2 2015 260 Thrombosis - Dormant Projects (Contd..8), H2 2015 261 Thrombosis - Dormant Projects (Contd..9), H2 2015 262 Thrombosis - Discontinued Products, H2 2015 263 Thrombosis - Discontinued Products (Contd..1), H2 2015 264 Thrombosis - Discontinued Products (Contd..2), H2 2015 265 Thrombosis - Discontinued Products (Contd..3), H2 2015 266
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
